What the Future Holds for NASH: An Augmented Reality Look into Disease Stating and Targeted Therapies
Premiere Date: Monday, December 23, 2019This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 31, 2020
Note: Credit Is No Longer Available
 | Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD, President, Inova Medicine Services Chairman, Clinical Research, Inova Health System Professor and Chairman of Department of Medicine Inova Fairfax Medical Campus Falls Church, VA |
 | Rohit Loomba, MD, MHSc Director, NAFLD Research Center Professor of Medicine Director of Hepatology and Vice Chief Division of Gastroenterology Adjunct Professor, Division of Epidemiology University of California at San Diego San Diego, CA |
 | Mazen Noureddin, MD, MHSc Director, Fatty Liver Program Karsh Division of Gastroenterology and Hepatology Comprehensive Transplant Center Cedars-Sinai Medical Center Los Angeles, CA |
Given the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and the societal and economic burden of its aggressive subtype, non-alcoholic steatohepatitis (NASH), it is important that hepatologists and gastroenterologists are equipped with the latest tools to diagnose NASH. While there are currently no approved therapies for the treatment of NASH, several targeted therapies are being investigated in clinical trials, with high probability of being approved in the near future. Hence, it is imperative that hepatologists and gastroenterologists have up to date knowledge regarding the latest clinical data on NASH therapies.
This CME Outfitters symposium will feature expert faculty integrating augmented reality (AR) to discuss pathways, therapeutic targets, and disease progression providing the learners with the best visual experience to enable them to integrate the latest tools for diagnosis and management of patients with NASH.
At the end of this CE activity, participants should be able to:
- Describe the role of immune, inflammatory, and metabolic pathways in the pathogenesis of NASH.
- Select appropriate non-invasive and invasive modalities for the identification of advanced fibrosis in patients with NAFLD.
- Evaluate the efficacy of emerging therapies for improving fibrosis in patients with NASH.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe the role of immune, inflammatory, and metabolic pathways in the pathogenesis of NASH.
- Determine appropriate non-invasive and invasive modalities for the identification of advanced fibrosis in patients with NAFLD.
- Evaluate the efficacy of emerging therapies for improving fibrosis in patients with NASH.
Supported by an educational grant from Intercept Pharmaceuticals.
Hepatologists, gastroenterologists, endocrinologists, diabetologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15) CEUs). Universal Activity Number:
Enduring: 0376-0000-19-038-H01-P
Type: knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring material
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Younossi reports he receives research support from Bristol-Myers Squibb Company; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc. He is a consultant for Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Siemens; Terns Pharmaceuticals, Inc.; and Viking Therapeutics.
Dr. Loomba reports his institution receives grants from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb Company; Cirius Therapeutics; Eli Lilly and Company; Galectin Therapeutics Inc.; Galmed Pharmaceuticals Ltd.; GE Healthcare Life Sciences; Genfit; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; GRAIL, Inc.; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Merck & Co., Inc.; NGM Biopharmaceuticals; NuSirt Biopharma; Pfizer Inc.; pH Pharma Co., Ltd.; Prometheus Laboratories Inc.; and Siemens. He is a consultant or advisory board member for Alnylam Pharmaceuticals, Inc./ Regeneron Pharmaceuticals Inc. ; Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Bird Rock Bio; Boehringer Ingelheim; Bristol-Myer Squibb Company; Celgene Corporation; Cirius Therapeutics; CohBar, Inc.; Conatus Pharmaceuticals Inc.; Eli Lilly and Company; Galmed Pharmaceuticals Ltd.; Gemphire Therapeutics Inc.; Gilead Sciences, Inc.; Glympse Bio; GNI Group Ltd.; GRI Bio; Inipharm, Inc.; Intercept Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Metacrine, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Prometheus Laboratories Inc.; Promethera� Biosciences; sanofi-aventis U.S. LLC; Siemens; and Viking Therapeutics, Inc. He the Co-founder of Liponexus, Inc.
Dr. Noureddin reports that he receives research support from Allergan; Bristol-Myers Squibb Company; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Galectin Therapeutics Inc.; Galmed Pharmaceuticals; GENFIT; Gilead Sciences, Inc.; Novartis; Shire and Zydus Pharmaceuticals, Inc. He is on the advisory board or speakers bureau for Abbott; Allergan; Blade Therapeutics; EchosensTM North America; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novartis; OWL; Pfizer Inc.; Roche Diagnostics, North America; and Siemens. He is a stock shareholder (directly purchased) of Ananetos and Viking Therapeutics, Inc.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Kavitha Ramachandran, PhD (planning Committee has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-095-122319-60
